Study results link frequent anti-VEGF injections, risk of cognitive impairment

Digital EditionOphthalmology Times: November 1, 2020
Volume 45
Issue 18

Interim data from a cross-sectional study raise concerns that repeated intravitreal injections of an anti-VEGF agent may be associated with a decline in cognitive health.

This article was reviewed by Subhransu K. Ray, MD, PhD

Interim data from a cross-sectional study raise concerns that repeated intravitreal injections of an anti-VEGF agent may be associated with a decline in cognitive health.

The findings from the first 143 patients with age-related macular degeneration (AMD) enrolled in the Brain Health Assessment in Macular Degeneration (BHAM) study were presented by Subhransu K. Ray, MD, PhD, at the virtual meeting of the American Society of Retina Specialists.

He reported that patients who received higher cumulative anti-VEGF injections performed significantly worse on a test of cognition.

Related: Saving memories: Do anti-VEGF agents contribute to cognitive loss?

“It is essential to remember that our study does not establish a causal link between cumulative doses of anti-VEGF injections and cognitive function, but the data demonstrate an association between higher treatment number and increased risk of mild cognitive impairment,” said Ray, who is with Bay Area Retina Associates, Clinical Trial Center, in Walnut Creek, California.

Ray added that investigators are continuing to enroll patients in this study, and these initial findings need to be validated using other cognitive tools and assays.

“Furthermore, we need to evaluate confounding factors such as the impact of even moderate vision loss in one eye,” Ray pointed out. “In addition, we have begun a prospective trial that is following 200 patients who are just initiating anti-VEGF injections.”

Study rationale
The BHAM study was undertaken considering that anti-VEGF agents injected into the vitreous are detectable in the systemic circulation at biologically active levels, that there is direct communication from the vitreous cavity to the central nervous system (CNS) in rare pathological states, and that VEGF has an essential role in CNS health.

“However, very little is known about how the normal vitreous-CNS barrier is affected by repeated intravitreal injections of anti-VEGF compounds,” Ray said. “Furthermore, despite the fact that millions of intravitreal injections are performed yearly in the United States, there have been no formal studies assessing the impact of these repeated injections on cognitive performance in this vulnerable age group.”

Related: (AAO) Considerations when using anti-VEGF for treating AMD

Ray wrote the BHAM study protocol that is enrolling patients aged 65 to 85 years with BCVA of 20/50 or better in at least 1 eye and a diagnosis of AMD.

Patients were ineligible if they had any history of CNS disease or previous systemic anti-VEGF exposure. The study is targeting enrollment of 100 patients with dry AMD and 300 patients with wet AMD.

Cognitive performance was evaluated using the Brain Health Assessment (BHA) test, which was developed at the University of California, San Francisco, School of Medicine and validated for use in research dementia care centers.

The BHA test is a 10-minute, tablet-based tool that has been shown to have high specificity and high sensitivity for detecting dementia and early cognitive impairment, exceeding the sensitivity of the Montreal Cognitive Assessment.

It includes subsets of memory, executive function and speed, visuospatial skills, and language. Results are generated as an age-adjusted Z-score.

Related: Same-day exams with anti-VEGF therapy key to QoL, cost savings for wet AMD

“The experience in our study using the BHA test also shows that cognitive testing can be effectively performed within the flow of a retina clinic,” Ray said.

Based on their BHA Z-score, patients in the study were categorized into groups of low, moderate, and high likelihood of having mild cognitive impairment.

They were also stratified into 4 groups based on the number of intravitreal anti-VEGF injections they received: 0 (n = 38), 1 to 10 (n = 41), greater than 10 (n = 64), and greater than 20 (n = 51).

Mean age was similar for the 4 injection subgroups (range 77.1 to 78.2 years), but the percentage of patients with a BHA score placing them at high likelihood of having mild cognitive impairment was higher in the group that had received greater than 10 intravitreal injections compared with both the group who had no injections and the group who had received 1 to 10 injections (45.3% versus 34.2% and 36.5%).

In the group that had received greater than 20 injections, 49% of patients had a high likelihood of mild cognitive impairment, Ray said.

Related: AAO 2020: Considerations when using anti-VEGF for treating AMD

Comparing mean Z-scores
Another analysis compared the mean Z-scores among the 4 intravitreal injection groups. It found that the Z-score was significantly lower (indicating higher likelihood of having mild cognitive impairment) for both the patients who had received greater than 10 injections and those who had received greater than 20 injections versus those who had none.

Ray noted that because of the limited sample size, analyses were not done to investigate potential differences in Z-scores with patients divided according to anti-VEGF agent received.

Furthermore, many patients switched anti-VEGF agents during the course of their treatment.

“Once the full enrollment is completed, we hope to be able to address several factors at a more granular level, including whether choice of anti-VEGF agent had any impact,” Ray said. “More importantly, we hope that the final data set will help us to address potential confounding factors, including the impact of vision loss itself on the BHA score.”

Related: Anti-VEGF therapy may prevent/delay radiation maculopathy in choroidal melanoma

Ray added that investigators also hope to further refine the analysis of injection number versus injection duration and even age-dependent risks.

“In the end, whether there is or is not a statistically significant risk associated with anti-VEGF injections, we feel this is a question that needs to be formally addressed,” he said.

In addition, Ray suggested topics for future studies to explore a potential biologic basis of an effect of intravitreal anti-VEGF injections on cognitive function. These would include targeted neuroimaging of the hippocampus in patients with high cumulative anti-VEGF exposure, careful examination of optic nerve integrity prior to and after repeated intravitreal injections, further preclinical studies, and direct evaluation for anti-VEGF agents in post-mortem CNS tissues and CSF from patients who have received numerous intravitreal anti-VEGF injections.

“Developing such assays is complicated and time consuming, but might be valuable as we pursue longer acting and constitutively expressed anti-VEGF agents,” he said.

Related: Probe of IRIS registry: Anti-VEGF injections key treatment for PDR

Maintain treatment protocols
Ray cautioned that clinicians should not allow this very preliminary interim analysis to alter treatment protocols, but rather to use it to be aware of a patient’s mental health during the course of therapy.

“Frankly, limiting appropriate anti-VEGF therapy resulting in unnecessary vision loss may be more of a risk factor on cognition,” he said.

In extending thanks to his colleagues for supporting the research, Ray said that any retina clinics interested in additional information or participating in the BHAM clinical trial may reach out to him at

Read more by Cheryl Guttman Krader

Subhransu K. Ray, MD, PhD
Ray has no relevant financial interests to disclose.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.